Rotigotine Restless Legs Syndrome Dose Finding Trial
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to demonstrate clinical efficacy of four different dosages of
SPM 962 1.125 mg, 2.25 mg, 4.5 mg and 6.75 mg (corresponding to 2.5 cm2, 5 cm2, 10 cm2 and 15
cm2 patch size respectively) in RLS subjects. It is anticipated that rotigotine (SPM 936)
will be more effective than placebo. The tolerability and safety of rotigotine will be
assessed.